出展展示会 : nano tech 2021
Ovensa uses its nanomedicine platform for the targeted delivery of RNA drugs.
Ovensa is a Canadian biotechnology company specialized in the delivery of RNA-based therapeutics to the brain using its TRIOZAN™ biopolymer nanomedicine platform. Ovensa currently works with 7 pharmaceutical companies, including 4 Japanese companies (one being Takeda Pharmaceutical) to formulate their drugs into nanoparticles using its TRIOZAN™ drug delivery platform.
製品・サービス 1 新製品
siRNA targeting Galectin-1 as a combination therapy with checkpoint inhibitors in head & neck cancer.
Gal-1 is a glycan-binding protein playing major roles in cancer by modulating different processes leading to metastasis, recurrence, enhanced cancer stem cell properties, resistance towards treatments (e.g. immunotherapy, chemotherapy, radiotherapy), and bad tumor prognosis.
TRIOZAN polymeric material to make nanoparticles for targeted drug delivery to the brain or other organs.
The TRIOZAN™ Platform leverages the polymeric chemistry science around Ovensa’s patented core polymer (N,N,N-Trimethyl Chitosan) to develop various precision and combination therapeutics to overcome performance and resistance challenges associated with various types of innovative drugs including RNA, mAb, and peptide based molecules.
20 Murdock Avenue, Aurora, ON, Aurora Canada L4G5E5
TEL : 1-416-728-9932